Updated information and services can be found at: In the 2004-2005 season, there was a large epidemic of the influenza B virus Yamagata group in Kobe, Japan. In hemagglutination inhibition tests, most of the clinical isolates from Kobe showed antigenicities similar to those of previous isolates (the vaccine-type virus). Only a few antigenic variants were isolated around the peak of the epidemic; however, Kobe residents developed antibodies against the variants during the season. The antigenic variants showed a one-point mutation of a nucleotide in the HA1 gene (C440A or G421A), which resulted in the substitution of one amino acid in the 150 loop of the HA molecule (T147N or G141R) . The 150 loop is one of four epitopes of the hemagglutinin molecule of the influenza B virus. We established a system to detect one-point differences in the nucleotides of the 150 loop by means of high-resolution melting curve analysis with LCGreen. With this system, the isolates were determined to be the vaccine-type virus, antigenic variants, or a mixture of both. Some isolates were shown to be mixtures although they had been recognized as the vaccine-type virus with the hemagglutination inhibition tests. Thus, the antigenic variants appeared in the early period of the epidemic and were cocirculating with the vaccine-type virus during the epidemic.
Influenza epidemics occur every winter in Japan, as in European and North American countries. Over the past 20 years, the influenza B virus has caused epidemics in humans, as have the H1 and H3 subtypes of the influenza A virus. Recent isolates of influenza B virus strains are divided into two large lineages in a phylogenic tree: one group is represented by B/Victoria/2/87 and the other by B/Yamagata/16/88 (5) . B/Victoria group strains were dominant in the 1980s, whereas B/Yamagata strains became dominant in the early 1990s (5, 10, 11, 20, 24, 29) . In 1994, B/Victoria strains reemerged in southern China. In Japan, in the 1996-1997 season, the first epidemic of B/Victoria occurred after the reemergence, and both B/Victoria and B/Yamagata strains were isolated in the same season (11) (12) (13) (14) (16) (17) (18) .
We have been studying the antigenicities of the influenza B virus with monoclonal antibodies (MAbs). By analyzing the amino acid sequences of the hemagglutinin (HA) molecule, we have previously reported that the antigenic variants of the influenza B virus appeared with a point nucleotide mutation of the HA1 gene which caused the substitution of an amino acid in the HA molecule (12) (13) (14) (16) (17) (18) . Since a three-dimensional model of the influenza A virus HA molecule was reported in the early 1980s (26) , the immunodominant antigenic sites of the influenza B virus HA have been determined by comparing its amino acid sequences with those of the influenza A virus HA (1, 6) . We have previously reported neutralizing epitope sites detected with MAbs 5H4 and 3A12 in the prominent region of HA (15) , which corresponds to "site A" of the influenza A virus HA. The recently reported crystal structure of the HA molecule of the influenza B virus shares an overall similarity and domain organization with that of the influenza A virus. There are four major epitopes, the 120 loop (amino acids [aa] 116 to 137), the 150 loop (aa 141 to 150), the 160 loop (aa 162 to 167), and the 190 helix (aa 194 to 202) (25) . The epitope sites of 5H4 and 3A12 have been determined to be in the 150 loop. The epitope sites are specific for B/Yamagata strains and were conserved from the late 1980s until the isolates that did not react to 5H4 by hemagglutination inhibition (HI) tests appeared in the 1998-1999 season. A single nucleotide mutation that created an amino acid substitution in the 150 loop (R149K) was responsible for modulating the 5H4 epitope (13) , and the R149K virus became a major isolate in the following B/Yamagata epidemic in the 2000-2001 season (14) . In contrast to 5H4, 3A12 possessed HI activities against R149K variants as well, and all of the 2000-2001 isolates in Kobe, Japan, reacted well to 3A12 on HI tests. On the other hand, the antigenic variants that appeared in the 2000-2001 epidemics revealed a point mutation in the 120 loop (D126N). With the plaque cloning method, one of the clinical isolates was shown to be a mixture of the vaccine-type virus and the antigenic variant (14) . This finding was confirmed by means of highresolution melting curve analysis with LCGreen (19) . This new technique clearly demonstrated that the vaccine-type virus and the antigenic variant were circulating together during the epidemic and that humans were exposed to the mixture.
Melting curve analysis is a recently introduced automated, high-throughput method for detecting single-nucleotide polymorphisms (SNPs). The importance of routine detection of genetic SNPs has been emphasized to identify drug responders or nonresponders and patients at increased risk for drug toxicity (4) . Therefore, a simple and rapid method of analyzing SNPs is needed. At the end of the 20th century, the fluorescent melting analysis of PCR in conjunction with real-time PCR was introduced (23, 27) and was followed by melting techniques using fluorescently labeled oligonucleotide probes (2, 9) . Then, highresolution melting curve analysis was reported as a convenient technique (3) . This technique is performed with closed tubes and can be completed in less than 15 min. It does not require real-time PCR instruments, allele-specific PCR, or fluorescently labeled oligonucleotides. The process is made possible by heteroduplexdetecting DNA dyes that can be used at saturating concentrations without inhibiting PCR. In particular, LCGreen was reported to be superior to other dyes, such as SYBR green I, ethidium bromide, SUBR gold, Pico green, TOTO-1, and YOYO-1 (28) . Wild-type and homozygous-mutant samples are distinguished by melting temperature (T m ) shifts.
As mentioned above, the antigenic variants of influenza B virus appear during the epidemic season and have been isolated from clinical specimens along with the vaccine-type strains (12, 14, 16) . With the virus plaque cloning method, it was demonstrated that the vaccine-type strains and the variants were present in isolates from individual patients (14, 16) . When the proportions of the two viruses with distinct antigenicities were not equal, the less prevalent virus was not always detected with the HI test or direct sequencing. Therefore, it was necessary to perform virus plaque cloning in order to detect the mixture-type isolates (16, 19) . However, the virus plaque cloning method requires considerable time and labor. The fact that the antigenic variants of the influenza B virus often appear with one-point mutations in the HA1 gene (12) (13) (14) (16) (17) (18) gave us the idea of applying the melting curve analysis with LCGreen to distinguish antigenic variants from vaccine-type strains. By this easy method, it became possible to determine in a short time a number of isolates to be vaccinetype strains, the antigenic variants, or a mixture of both. In addition, the proportions of the antigenic variants in the mixture-type isolates were estimated (19) .
In the 2004-2005 season, a large epidemic of B/Yamagata occurred in Japan. This epidemic was as large as the epidemics in the late 1980s, when B/Yamagata caused the first epidemic in Japan. However, most of the isolates were vaccine-type viruses. Only a small number of antigenic variants were obtained around the peak of the epidemics. By means of melting curve analysis with LCGreen, we studied whether the variants were cocirculating with the vaccine-type virus from the earlier period of the epidemic. HI tests. HI tests were performed with antibodies treated with a receptordestroying enzyme (Takeda Chemical Industries Ltd., Osaka, Japan) and guinea pig red blood cells. The HI titer is the reciprocal of the antibody dilution (21).
MATERIALS AND METHODS

Viruses
Treatment with 3A12.
The isolates were treated with 3A12 by modifying the method of inducing escape mutants (1, 8) . Instead of 1 ϫ 10 5 CFU/ml of virus being incubated (15), 1 ϫ 10 4 CFU/ml of virus was incubated for 1 h at 37°C in the presence or absence of 10 l of 3A12. The virus-MAb mixture was inoculated in MDCK cells in 24-well plates and incubated at 35°C for 6 days. When the virus was recovered from wells inoculated with 3A12-treated virus, the HI tests were performed separately with 3A12.
Direct sequencing of virus RNA. RNA was obtained from 140 l of the isolated virus, and HA1-specific DNA was amplified with a Qiagen OneStep RT-PCR kit (Qiagen, Tokyo, Japan). Then, the products were sequenced with a BigDye Terminator v1.1 cycle sequencing kit (ABI, Tokyo, Japan) and analyzed with an ABI Prism 310 automatic sequencer (ABI). As sequencing of the HA1 regions was carried out in two sections, two primer sets were prepared: 5Ј CTACTCATGGTAGTAACATCC and 3Ј TGGAACCCCCAAACAGTAATT for the first half and 5Ј AATGGCTTGGGCTGTCCCAA and 3Ј CCCCTTTC CTTTAATAGTTTTGC for the second half.
High-resolution melting curve analysis. High-resolution melting curve analysis was performed as described previously (17) . The primers were designed with the software program Primer Express (ABI). The sequences of the primer pairs for the 150 loop were (forward) CAGGAGGACCCTACAGACTTGG (nucleotides [nt] 392 to 413) and (reverse) TTGTTGCGAAAAATCCGCTT (nt 466 to 446), and the size of the amplified DNA was 75 bp (nt 392 to 446), which corresponds to 24 aa (aa 132 to 155). The primers were designed specifically for the 150 loop (aa 141 to 150), and the amplicon does not encompass the 160 loop (aa 161 to 167). A PCR mixture was made in 10 l containing 0.3 M of each primer, 0.2 mM of each deoxynucleoside triphosphate, 2 mM MgCl 2 , 500 g/ml bovine serum albumin, 0.5 U of Ultra-Pfu polymerase (Stratagene, Tokyo, Japan), reaction buffer (Stratagene), 1ϫ LCGreen I (Idaho Technology, Salt Lake City, UT), and 10 ng of amplified DNA. Capillary tubes (Roche Diagnostic Inc., Tokyo, Japan) containing reaction mixtures were thermally cycled with a Rapid Cycler 2 instrument (Idaho Technology), with maximum-temperature ramping under the following conditions: initial holds at 98°C for 2 min, followed by 35 cycles at 95°C for 2 s, 62°C for 2 s, and 72°C for 3 s. After amplification, the capillary tubes were transferred to a high-resolution melting instrument (HR-1; Idaho Technology) and heated by increasing the temperature at the programmed rate of 0.3°C/s to acquire fluorescence data during DNA melting. The data were exported into HR-1 analysis software through a custom interface, and derivative melting curve plots were displayed. A variation of 0.5°C to 0.7°C was observed between experiments, and therefore T m shifts were observed from the control curves. As controls, the curves for B/Kobe/67/2005 are shown in Fig. 2 Genetic analysis. Further analyses were performed with 17 strains isolated from patients aged 31 to 59 years. First, the nucleotide sequence (nt 6 to 1008) and the deduced amino acid sequence of the HA1 gene were analyzed and were compared with those of strains isolated in the previous seasons (Fig. 1) . The nucleotide sequences in the 150 loop (nt 421 to 447) of 14 isolates (DDBJ accession no. AB385603, AB385605, and AB426532 to AB426543) were exactly the same as those of the previous 2 isolates, B/Kobe/87/2001 and B/Kobe/3/2004 (AB071620 and AB381880), whereas three antigenic variants showed single nucleotide mutations that corresponded to amino acid substitutions. B/Kobe/103/2005 (AB385604), which did not react to 3A12, had a nucleotide mutation, C440A, corresponding to an amino acid substitution, T147N. B/Kobe/113/2005 and B/Kobe/115/2005 (AB385607 and AB385608), which reacted with 3A12 at lower titers, had a nucleotide mutation, G421A, corresponding to an amino acid substitution, G141R. Treatment with high-dose 3A12. Next, 17 strains were treated with 3A12 by means of a method similar to that for inducing laboratory mutants (15) Figure 4 shows the curves of other isolates that the HI tests had shown to be vaccine-type viruses. The curves of the majority of the isolates were very close to the curve of B/Kobe/ 67/2005, suggesting that they comprised mostly vaccine-type virus. However, the curves of a few isolates were rather close to the curve of B/Kobe/39/2005, suggesting that a small amount of the antigenic variants was present in the isolates.
DISCUSSION
For the past 10 years in Japan, an epidemic of the influenza A virus, either subtype H1 or subtype H3, has occurred every year, and an epidemic of the influenza B virus, either the Victoria or the Yamagata group, has occurred every other year. One major reason for the repeated epidemics is that the different types of virus cause them in turn. In addition, the viral antigenicities vary from season to season. In particular, the antigenicities of the influenza A virus vary frequently. In contrast, the antigenicities of the influenza B virus are relatively stable (10, 11) . This stability might be due to the fact that the influenza B virus does not possess the abundant reservoirs that the influenza A virus does. The influenza B virus has been isolated primarily from humans, except for a few isolates from seals (22) . Therefore, the antigenic variants of the influenza B virus are suggested to be created in humans. We have been studying the antigenicities of field isolates of the influenza B virus in Japan for the past 10 years. The antigenic variants appeared during the epidemic season, usually with a point mutation of a nucleotide in the HA1 gene, which resulted in an amino acid substitution. Then, some of the variants became major isolates in subsequent seasons (12, 14, 15, 17) . As mentioned in the introduction, the neutralizing epitope of 3A12 specific for B/Yamagata has been conserved since the late 1980s. We speculate that the established and accumulated human immunities began to induce the naturally occurring antigenic variants by modulating the 3A12 epitope. Fig. 1; Table 1 ). The isolates reacted to 3A12 as well. A similar tendency was observed throughout Japan in that 97% of all Japanese isolates were vaccine-type viruses (7) . In spite of the fact that only a few antigenic variants were isolated, the residents of Kobe acquired antibodies against them during the season. How can these discrepancies be explained? We postulate three reasons for the discrepancies. First, the 2004-2005 epidemics started almost a month late in Japan. The number of cases of influenza began to increase in the beginning of February and peaked in the middle of March. The doctors in the surveillance point clinics, who were ready for the epidemic in the beginning of January, collected a number of clinical specimens when the patients began visiting the offices. Therefore, 80% of the influenza B isolates were obtained before the peak of the epidemics. It is possible that the antigenic variants were isolated in greater numbers in the latter half of the epidemic. Second, most of the clinical specimens were obtained from children younger than 16 years. The reason is that the majority of the surveillance point clinics were pediatric offices. As explained in the introduction, B/Yamagata epidemics occurred in the 1998-1999, 2000-2001, and 2004-2005 seasons. Because the 2000-2001 epidemic was not so large, children younger than 6 years might not have been exposed to the B/Yamagata strains. They were naïve for the vaccine-type virus. Thus, it is possible that these children were infected with the vaccine-type virus, even when both the vaccine-type virus and the antigenic variants were circulating. Finally, the HI tests have a technical problem. When the viruses with distinct antigenicities are present in the isolates of single patients and the proportions of the two viruses are not equal, the less prevalent virus is not always detected with the HI test (12, 14) . For example, two strains in the 2000-2001 season were found to be mixtures of the antigenic variants and the vaccine-type virus at a ratio of 2:1 by means of melting curve analysis with LCGreen, although they had been identified as antigenic variants with the HI test and direct sequencing (19) . In these cases, the presence of the vaccine-type virus was not detected with the HI test. Therefore, in the case of the 2004-2005 isolates, the presence of the antigenic variants may not have been detected with the HI test with 3A12.
For these reasons, we selected 17 strains isolated from patients aged 31 to 59 years and analyzed them further. First, the strains were treated with a high dose of 3A12. The fact that B/Kobe/39/2005 was not completely neutralized with 3A12 suggested that antigenic variants were present. However, the escaping mutants might have been induced by treatment with 3A12. Therefore, B/Kobe/39/2005 was analyzed further by means of melting curve analysis with LCGreen and was found to be a mixture of the vaccine-type virus and the antigenic variant (Fig. 2) . Furthermore, some other strains were found to be mixtures, although the proportions of the variants were lower (Fig. 4) . B/Kobe/103/2005, an antigenic variant, was isolated at the peak of the epidemic; however, B/Kobe/39/2005, a mixture strain, was obtained in the beginning of the season. Therefore, the antigenic variants had already appeared in the early period of the epidemic and were circulating with the vaccine-type virus. We speculate that the antigenic variants were selected under human immunity, when persons with acquired antibodies were infected with the mixture virus. This might explain why the B/Yamagata epidemic in the 2004-2005 season was so large.
We have speculated that the antigenic variants appeared during the epidemic season and that they became major isolates in subsequent seasons (12, 16, 17) . By means of melting curve analysis with LCGreen, the appearance of the antigenic variants was detected dynamically. This novel technique allows us to analyze the antigenic shifts more precisely. The information will benefit public health management, especially from the perspective of selecting suitable strains for vaccines and predicting the scale of future epidemics.
